Numerous studies investigating PAR4 antibodies, PAR4 point mutations, or PAR4 antagonists (in patients with coronary artery disease) have shown antithrombotic effects [[56], [57], [58], [59], [60], [61]]. The gene discussed is F2RL3; the disease is coronary artery disorder.